EMA Authorised: Kinpeygo (budesonide, micronised) — Stada Arzneimittel AG

View source ↗

Summary

The European Medicines Agency authorised Kinpeygo, a budesonide, micronised formulation, for IgA nephropathy, with orphan designation, developed by Stada Arznei…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Kinpeygo (budesonide)

Snippet

Status: Authorised. Therapeutic area: Glomerulonephritis, IGA. MAH: Stada Arzneimittel AG. Decision date: 19/03/2026. Orphan medicine